| Tumor angiogenesis: causes, consequences, challenges and opportunities R Lugano, M Ramachandran, A Dimberg Cellular and Molecular Life Sciences 77, 1745-1770, 2020 | 1752 | 2020 |
| Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer J Ma, M Ramachandran, C Jin, C Quijano-Rubio, M Martikainen, D Yu, ... Cell death & disease 11 (1), 48, 2020 | 170 | 2020 |
| Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma L van Hooren, A Vaccaro, M Ramachandran, K Vazaios, S Libard, ... Nature Communications 12 (1), 4127, 2021 | 111 | 2021 |
| Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice V Hillerdal, M Ramachandran, J Leja, M Essand BMC cancer 14, 1-9, 2014 | 93 | 2014 |
| Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer C Jin, G Fotaki, M Ramachandran, B Nilsson, M Essand, D Yu EMBO molecular medicine 8 (7), 702-711, 2016 | 78 | 2016 |
| Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma M Ramachandran, A Vaccaro, T van de Walle, M Georganaki, R Lugano, ... Cancer Cell 41 (6), 1134-1151. e10, 2023 | 68 | 2023 |
| Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted oncolytic semliki forest virus M Ramachandran, D Yu, M Dyczynski, S Baskaran, L Zhang, A Lulla, ... Clinical Cancer Research 23 (6), 1519-1530, 2017 | 63 | 2017 |
| Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures D Yu, C Jin, M Ramachandran, J Xu, B Nilsson, O Korsgren, K Le Blanc, ... PLoS One 8 (1), e54952, 2013 | 51 | 2013 |
| CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers C Jin, J Ma, M Ramachandran, D Yu, M Essand Nature Biomedical Engineering 6 (7), 830-841, 2022 | 50 | 2022 |
| The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells M Ramachandran, A Dimberg, M Essand Seminars in Cancer Biology 45, 23-35, 2017 | 49 | 2017 |
| An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors M Ramachandran, D Yu, A Wanders, M Essand, F Eriksson Molecular Therapy 21 (11), 2008-2018, 2013 | 48 | 2013 |
| Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration M Ramachandran, C Jin, D Yu, F Eriksson, M Essand The Journal of Immunology 193 (5), 2287-2296, 2014 | 47* | 2014 |
| Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy M Georganaki, M Ramachandran, S Tuit, NG Núñez, A Karampatzakis, ... Oncoimmunology 9 (1), 1730538, 2020 | 38 | 2020 |
| Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses G Fotaki, C Jin, M Ramachandran, IK Kerzeli, A Karlsson-Parra, D Yu, ... Oncoimmunology 7 (3), e1395126, 2018 | 28 | 2018 |
| Tertiary lymphoid structures in the central nervous system: implications for glioblastoma T Van de Walle, A Vaccaro, M Ramachandran, I Pietilä, M Essand, ... Frontiers in immunology 12, 724739, 2021 | 27 | 2021 |
| IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma M Martikainen, M Ramachandran, R Lugano, J Ma, MM Martikainen, ... Molecular Therapy-Oncolytics 21, 37-46, 2021 | 26 | 2021 |
| Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in … G Fotaki, C Jin, IK Kerzeli, M Ramachandran, MM Martikainen, ... Oncoimmunology 7 (3), e1397250, 2018 | 24 | 2018 |
| Complementarity-determining region clustering may cause CAR-T cell dysfunction T Sarén, G Saronio, P Marti Torrell, X Zhu, J Thelander, Y Andersson, ... Nature Communications 14 (1), 4732, 2023 | 19 | 2023 |
| ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma H Huang, M Georganaki, LL Conze, B Laviña, L van Hooren, K Vemuri, ... Neuro-oncology 24 (3), 398-411, 2022 | 14 | 2022 |
| Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus J Ma, C Jin, M Čančer, H Wang, M Ramachandran, D Yu Molecular Therapy-Oncolytics 21, 356-366, 2021 | 11 | 2021 |
Magnus EssandProfessor of Gene Therapy, Uppsala Universityigp.uu.se üzerinde doğrulanmış e-posta adresine sahip